Clinical relevance of serum omentin‐1 levels as a biomarker of prognosis in patients with acute cerebral infarction

BACKGROUND AND PURPOSE: Previous studies have shown that adipocytokines are associated with atherosclerosis, diagnosis, and functional prognosis after ischemic stroke. However, few studies have investigated the relationship between omentin‐1 and atherosclerotic acute cerebral infarction (ACI). METHODS: In this study, we investigated the association between serum omentin‐1 levels at admission and severity, infarction volume, and functional prognosis of patients 90 days after atherosclerotic ACI. RESULTS: A total of 109 patients with atherosclerotic ACI were enrolled. Serum omentin‐1 levels at admission were lower in patients with ACI than those in healthy controls (47.18 ± 13.64 vs. 56.27 ± 34.44 ng/ml, p = .014). Serum omentin‐1 levels at admission were negatively correlated with severity of ACI (r = −.271, p = .004) and infarction volume (r = −.264, p = .006), respectively. Moreover, serum omentin‐1 levels were lower in the poor functional prognosis group than those in the good functional prognosis group in patients with large artery and small artery atherosclerotic ACI. In a logistic regression analysis, higher serum omentin‐1 level (>43.10 ng/ml) at admission was negatively associated with a poor functional prognosis 90 days after atherosclerotic ACI. CONCLUSIONS: Serum omentin‐1 levels at admission were significantly lower among patients with ACI. A higher plasma omentin‐1 level (>43.10 ng/ml) was negatively associated with poor functional prognosis 90 days after atherosclerotic ACI. Further studies are needed to investigate the pathophysiological mechanism of omentin‐1 in affecting attacks and prognosis of ACI as well as to confirm the value of plasma omentin‐1 level as a potential biomarker.